Cogent Biosciences (COGT) Enterprise Value (2017 - 2026)

Cogent Biosciences' Enterprise Value history runs 10 years deep, the most recent figure standing at -$866.4 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 252.67% year-over-year to -$866.4 million; the TTM figure through Mar 2026 stood at -$866.4 million (down 252.67% YoY), while the FY2025 annual figure was -$900.8 million, down 213.77% from the prior year.
• Enterprise Value was -$866.4 million for Q1 2026 at Cogent Biosciences, up from -$900.8 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$141.8 million in Q3 2022 to a low of -$900.8 million in Q4 2025.
• Historically, Enterprise Value has averaged -$354.0 million across 5 years, with a median of -$287.1 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Enterprise Value surged 43.62% in 2025, then slumped 252.67% in 2026.
• A 5-year view of Enterprise Value shows it stood at -$259.3 million in 2022, then declined by 2.48% to -$265.7 million in 2023, then decreased by 8.04% to -$287.1 million in 2024, then sank by 213.77% to -$900.8 million in 2025, then advanced by 3.82% to -$866.4 million in 2026.
• The last three Enterprise Value figures came in at -$866.4 million (Q1 2026), -$900.8 million (Q4 2025), and -$390.9 million (Q3 2025), per Business Quant data.